Home  |  Publications  |  Conferences   |  Join  |  Contact
ISSN: 2153-0645

Journal of Pharmacogenomics & Pharmacoproteomics

Open Access
home » pharmacogenomics-pharmacoproteomics

Upcoming Special Issues

Special issue entitled: "Personalised Medicine" has been edited by
Editor Image

Leslie Cole Manace
Department of Genetics
Kaiser Permanente Oakland Medical Center
Tel. 510-752-2029
Fax 510-752-6754
E-mail: Leslie.C.Manace@kp.org

University Logo
Special issue entitled: "Epigenetics" has been edited by
Editor Image

Ahmed Esmat Abdel Moneim
Arab Republic of Egypt
Zoology & Entomology Department
Helwan University-Ain Helwan
11795 Cairo

University Logo
Read More»

About the Journal

The Journal of Pharmacogenomics and Pharmacoproteomics publishes articles on new innovations in the field of personalized medicines. The original research articles or current reviews published under the journal deals with the influence of genetic variations on drug response in patients and viceversa. The journal aims to publish innovations in customized drug discovery using proteome technology. The journal provides an open access platform to publish latest advancements in the field of drug design, drug development and drug delivery.
Journal of Pharmacogenomics & Pharmacoproteomics is an open access and peer reviewed journal includes a wide range of field in its discipline to create a platform for the authors to make their valuable contributions towards the journal and the peer review process promises the publishing of quality, reliable and important articles for the readers and authors of scholarly, academic and scientific field.
The Journal of Pharmacogenomics and Pharmacoproteomics welcomes new innovations including but not limited to the field of drug development, pharmacogenomics, pharmacoproteomics, new discoveries in genomic targets, various drug responses due to genetic polymorphisms, chemogenomics, personalized medicines, drug dosage formulations, drug safety and its efficacy.
Pharmacogenomics and Pharmacoproteomics Journal is at higher echelons that enhance the intelligence and information dissemination on topics closely related to Pharmacogenomics and Pharmacoproteomics. They provide a unique forum dedicated to scientists to express their research articles, review articles, case reports and short communications on an array of Pharmacogenomics and Pharmacoproteomics research. The Pharmacogenomics and Pharmacoproteomics Peer Reviewed Journal is proficiently supported by universally prominent Editorial Board members. Pharmacogenomics and Pharmacoproteomics journal impact factor is mainly calculated based on the number of articles that undergo a double blind peer review process by competent Editorial Board so as to ensure excellence, essence of the work and number of citations received for the same published articles. Abstracts and full texts of all articles published by Pharmacogenomics and Pharmacoproteomics Open Access Journals are freely accessible to everyone immediately after publication.
OMICS International group is delighted to invite you to attend the 3rd International Conference on Genomics and Pharmacogenomicsduring september 21-23, 2015 San Antonio, USA.
OMICS International organises 300+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies, 400+ symposiums and Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.
Submit manuscript at http://editorialmanager.com/omicsgroup/ or send as an email attachment to the Editorial Office at editor.jpp@omicsonline.org
*Unofficial 2013 Impact Factorwas established by dividing the number of articles published in 2011 and 2012 with the number of times they are cited in 2013 based on Google search and the Scholar Citation Index database. If ‘X’ is the total number of articles published in 2011 and 2012, and ‘Y’ is the number of times these articles were cited in indexed journals during 2013 than, impact factor = X/Y
Aims and Scope

Recently published articles

Polymorphisms in Genes Encoding Metalloproteinase 9 and Lymphotoxin- Alpha can Influence Warfarin Treatment

Jéssica B Borges, Thiago DC Hirata, Alvaro Cerda, Cristina M Fajardo, Raony CC Cesar, João ID França, Jéssica C Santos, Hui-Tzu L Wang, Lara R Castro, Marcelo F Sampaio, Rosario DC Hirata, Mario H Hirata

© 2008-2015 OMICS Group - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version